PBSV · CIK 0001304161 · FY2025 live · 2025-10-31
Pharma-Bio Serv, Inc.
View as
Model
Z″
FY2025
14.99
Zone
Safe
Prior
—
Market DD
—
1y PD
—
14.99
Classic Z 6.72
Z″ 14.99 · distress below 1.10, grey to 2.60, safe above.
Z″ factor contributions
X1 Working capital / assets
Short-term liquidity. Carries more weight in Z″ than in classic Z.
0.856.56 × = 5.60X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
0.773.26 × = 2.52X3 EBIT / assets
Operating return on assets. Highest weight in Z″.
−0.056.72 × = −0.31X4 Book equity / liabilities
Book equity versus the liability stack. Sales / assets is omitted so asset-light names are not punished for turnover.
6.851.05 × = 7.19
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Pharma-Bio Serv, Inc. is on Z″ at 14.99 (safe) for FY2025, from an SEC 10-K. Book equity / liabilities is the line that sets the print; working capital / assets is the runner-up. This is the first live year on the desk. No market tape loaded. Z″ drops sales/assets so asset-light names are not punished for turnover. X4 is book equity on every name.
Book screen Safe; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Z″ scores · 97th percentile in Industrials.
KPI widgets
Current assets
$13M
Total assets
$14M
Current liabilities
$2M
Total liabilities
$2M
Working capital
$12M
Retained earnings
$11M
EBIT
−$638K
Total sales
$9M
Book equity
$12M
Accession 0001654954-26-000710. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-10-31). Z″ is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.